Condition

Clinical trials for Obesity or Overweight

Active public studies that list Obesity or Overweight as a condition.

10active studies

7recruiting now

15countries represented

218largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Ulcerative Colitis, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937086See eligibility →

Recruiting nowPhase 3

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Crohn's Disease, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium183 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937099See eligibility →

Recruiting nowPhase 3

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Obesity or OverweightCondition

Maridebart CafraglutideTreatment

Puerto Rico, United States45 locations

AmgenSponsor

Updated 2026-08-27 · NCT07575399See eligibility →

Recruiting nowPhase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Obesity or OverweightCondition

AZD6234, PlaceboTreatment

Argentina, Australia212 locations

AstraZenecaSponsor

Updated 2026-08-25 · NCT07784725See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Obesity or OverweightCondition

Placebo, EnicepatideTreatment

Argentina, Australia195 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351045See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity or Overweight, Type 2 Diabetes MellitusCondition

Placebo, EnicepatideTreatment

Argentina, Australia193 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351058See eligibility →

Recruiting nowPhase 1

Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection

Obesity or OverweightCondition

GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tabletsTreatment

China1 locations

Gan & Lee Pharmaceuticals.Sponsor

Updated 2025-12-12 · NCT07128888See eligibility →

Opening soonPhase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Obesity or Overweight, Diabetes Mellitus, Type 2Condition

AZD6234, PlaceboTreatment

Argentina, Australia218 locations

AstraZenecaSponsor

Updated 2026-08-25 · NCT07784270See eligibility →

Opening soonPhase 3

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

Obesity or Overweight, Weight-Related ComorbidityCondition

AZD6234, PlaceboTreatment

Argentina, Brazil88 locations

AstraZenecaSponsor

Updated 2026-08-20 · NCT07776509See eligibility →

Opening soonPhase 2

A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight

Obesity or OverweightCondition

Petrelintide, EnicepatideTreatment

Locations pending0 locations

Hoffmann-La RocheSponsor

Updated 2026-08-07 · NCT07589686See eligibility →

Related conditions

Obesity1,102 Obesity & Overweight220 Overweight205 Overweight and Obesity130 Type 2 Diabetes108 Hypertension107

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.